Biosimilar Newsletter Archive
-
04.09.26 -- Trends In FDA 2025 Warning Letters
4/9/2026
04/09/26
-
04.02.26 -- The Hidden Engineering Behind Successful Upstream Bioprocessing
4/2/2026
04/02/26 Biosimilar Development Newsletter
-
03.26.26 -- A simple, helpful look at PUPSIT implementation.
3/26/2026
03/26/26 Biosimilar Development Newsletter
-
03.26.26 -- A Practical Look At Modern Downstream Processing For Biologics
3/26/2026
03/26/26 Biosimilar Development Newsletter
-
03.24.26 -- Stop Engineering Cells. Start Engineering Glycans.
3/24/2026
03/24/26 Biosimilar Development Newsletter
-
03.19.26 -- Struggling with mAb aggregation and other impurities?
3/19/2026
03/19/26 Biosimilar Development Newsletter
-
03.19.26 -- A Novel In Vitro Glycosylation Approach For Difficult PTMs
3/19/2026
03/19/26 Biosimilar Development Newsletter
-
03.05.26 -- Phase-Appropriate Control Lessons For mAb/ADC Manufacturers
3/5/2026
03/05/26 Biosimilar Development Newsletter
-
02.26.26 -- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
2/26/2026
02/26/26
-
02.19.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?
2/19/2026
02/19/26 Biosimilar Development Newsletter